EMA Strengthens Conflict of Interest Policies
Posted 26 March 2012 | By
The European Medicines Agency (EMA) announced Monday, 26 March its Management Board has endorsed a proposal from EMA Executive Director Guido Rasi to strengthen conflict of interest policies surrounding its scientific committee members and experts.
The Management Board also adopted several other initiatives, including a transparency initiative to "increase the transparency of all pharmacovigilance activities of the Agency and national authorities" while implementing the new pharmacovigilance legislation.
Among the other initiatives adopted:
- distinctions are made between conflicts involving academic/public research and conflicts involving pharmaceutical industry
- a new "breach of trust" procedure for participants falsely declaring no conflicts of interest
- additional checks on the accuracy of declared conflicts of interest
EMA - European Medicines Agency Management Board strengthens conflicts of interest policies and transparency